Drugs / LAE103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07230496 | Dec 2025 → Mar 2028 expected | — | Laekna Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | Laekna Limited | Regulatory Laekna Announces IND Approval of LAE103 (an ActRIIB selective antibody) for Sarcopenic Obesity and Muscle Related Disease by FDA
Laekna Announces IND Approval of LAE103 (an ActRIIB selective antibody) for Sarcopenic Obesity and Muscle Related Disease by FDA laekna.com ↗
July 31, 2025 — Laekna (2105.HK) announced today that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE103, an internally discovered monoclonal antibody against ActRIIB for the treatment of sarcopenic obesity and muscle related disease. |
| 2025-06-30 | Laekna Limited | Regulatory Laekna Submitted Investigational New Drug Application to FDA for LAE103 for Sarcopenic Obesity and Muscle Related Disease
Laekna Submitted Investigational New Drug Application to FDA for LAE103 for Sarcopenic Obesity and Muscle Related Disease laekna.com ↗
Laekna (2105.HK) announced today that the company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LAE103, an internally discovered monoclonal antibody against ActRIIB for the treatment of patients with sarcopenic obesity and muscle related disease. |
| 2025-06-23 | Laekna Limited | Results ADA 2025 | Laekna Presented Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123
ADA 2025 | Laekna Presented Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123 laekna.com ↗
A synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA-IIB dual-specific antibody LAE123 |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAE103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230496 ↗ |
| Route | Subcutaneous | “LAE103 injection, subcutaneous (SC) injection” NCT07230496 ↗ |